Reference is made to the stock exchange notice dated 18 January 2010 regarding
the final result in the subsequent offering in NorDiag ASA. The share capital
increase of NOK 8,000,000 has now been registered with the Norwegian Register of
Business Enterprises (Nw.: Foretaksregisteret). As a consequence, the new
registered share capital of NorDiag is NOK 62,065,282, divided into 62,065,282
shares, each with a par value of NOK 1.00.

The new shares in NorDiag are registered in the Norwegian Central Securities
Depository (VPS) and are listed on Oslo Børs today.


Contact:          CFO Tone Kvåle        Phone: +47 915 19576


About NorDiag:

NorDiag is a biotechnology company developing, manufacturing and marketing
automated solutions (instruments and tests) for sample preparation of DNA from
difficult biological samples. DNA diagnostics give more rapid and precise
answers,  and is the fastest growing field within diagnostics. The company's
sample preparation solutions are today used in connection with STI,
tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large
and small laboratories. NorDiag was founded in 2003 and has its headquarters in
Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in
West Chester (PA), USA and in Vienna, Austria. The group has today 40.1
man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.
For further information, please seewww.nordiag.com <http://www.nordiag.com>.


This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)


[HUG#1377199]